ADAP Bullish Divergence, Low Risk PlayBullish divergence on the MACD and ADX.
Price near last low.
Low risk play with high potential in the short term.
0%
0%
0%
0%
0%
−0.5406USD
−165.354MUSD
27.131MUSD
195.37M
About Adaptimmune Therapeutics plc
Sector
Industry
CEO
Adrian Rawcliffe
Website
Headquarters
Abingdon
Employees
407
Founded
2008
ISIN
US00653A1079
Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company. It engages in the provision and development of novel cell therapies and novel cancer immunotherapy products to people with cancer. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
$ADAP is gonna fall todayPupm&Dump trading strategy idea.
$ADAP is rising too much today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $6,29;
stop-loss — $6,52;
take-profit — $5,82/MOC
Do not view
$ADAPDragon pattern.
Weekly classic bullish divergence on the MACD.
Stop = Close below resistance
1st Target = Resistance/0.236 fib extension
2nd Target = Resistance/0.5 fib extension
BUY ADAP - ADAPTIMMUNE THERAPEUTICS - STRONG BUY ON WEEKLY CHARTBUY ADAP - ADAPTIMMUNE THERAPEUTICS - STRONG BUY ON WEEKLY CHART
A Fantastic Bullish Setup on ADAPThis stock has shown breakout earlier creating wave 1
then it created its wave 3 when it had its stronger breakout
now its doing a flat sideways tight range wave 4
The NEXT breakout will be a wave 5 up
SPEAR T-cell Platform Delivers Initial Responses in Four Solid TAdaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
--------------------------------------------------------------
Partial Responses seen in liver, melanoma, gastro-esophageal junction, and head and neck cancers.
-------------------------------
SPEAR T-cells Targeting MAGE-A4 Demonstrate New Responses in EGJIn the Surpass trial, three of the first four patients treated with ADP-A2M4CD8 had smaller tumors at the last checkup than they did at the outset.
----------------------------------------------------------
Eight out of 16 patients with synovial sarcoma have shown partial responses to treatment wit
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
